Testosterone Measurement Discordance Leads to Poor Clinical Decisions – Are You Castrated and Why It Matters?

The only way to make these significant clinical decisions with confidence is to be sure that before assuming that you are castrate resistant your testosterone levels must be confirmed by either mass spectrometry or an immunoassay method that has been validated at low testosterone levels and interpreted with caution before any changes are made to treatment management. 

Apalutamide (Erleada® ) Approved for Metastatic Castrate Sensitive Prostate Cancer

The Food and Drug Administration (FDA) approved apalutamide (ERLEADA), for men with metastatic castration-sensitive prostate cancer (mCSPC).

PROCEED Registry Show Men with Low PSA Scores Have a Median Survival Longer Then Four Years

Results from the PROCEED registry found that men with advanced prostate cancer with low PSA had a median survival of nearly 4 years after treatment with PROVENGE® (sipuleucel-T). A median survival means that one half of the men who participated in the registry lived longer than four years.

Using Radioactive Particles to Kill Cells Attached to a ‘Homing Device’ to Seek Out Cancers

Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports.

An emerging class of drugs are made up of a radioactive particle that can kill cells attached to a ‘homing device’ to seek out cancers by detecting the presence of a target molecule on their surface.

Urinary Incontinence Post Radical Prostatectomy (RP) - Solutions

There are Solutions

One of the possible side effects you might experience after having prostate cancer surgery or radical prostatectomy or RP is incontinence. Incontinence or the unwanted leakage of urine can be just a minor dripping of urine, or it can be the complete and total loss of control of your urine.

Adjuvant Radiotherapy Cuts Prostate Cancer Recurrence Risk 

The adjuvant group had a significant 74% decreased the risk of biochemical recurrence compared with the observation arm. The 10-year overall survival rates did not differ significantly between the adjuvant and observation groups (92% and 87%, respectively).

The FDA has Agreed to Grant A Priority Review of Xtandi for Men Who are Castrate Sensitive

According to a press release issued by Astellas and Pfizer that the FDA has granted a priority review to enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer.

PSMA Scan Looks Superior to An Axumin Scan in Men with A Prostate  Cancer Recurrence

We should note that the two scans performed equally well in men who had their recurrence only in the prostate bed.  However, the trial also showed that the PSMA PET scan detected more cancerous pelvic lymph nodes and non-regional metastases.

Is Aloe Vera for Radiotherapy-Related Skin Reactions Effective?

Research shows that aloe vera alone is ineffective and may worsen skin reactions from radiation treatment. Research has shown that the cleansing the skin daily with mild moisturizing soaps is most beneficial. 

Germline Mutations As Prognostic Indicators of Castrate Resistance

In summary, these results demonstrate worse outcomes in men with germline BRCA2 and CHEK2 mutations compared with men without these mutations when treated with standard first-line ADT with LHRH analogs.

Evaluating PSMA-Targeted Radionuclide Therapy

This study did demonstrate that the level of PSMA expression of a man’s prostate cancer, the stronger the association with the likelihood of their having a PSA response. 

Is There A Role for Testosterone Therapy in the Treatment of Metastatic Prostate Cancer?

There has long been a discussion about the possible effects of using testosterone as a treatment for men with advanced metastatic prostate cancer.  In a poster presentation at ASCO 2019, it was shown that there are androgen receptor changes in the circulating-tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone. 

ADT With and Without Xtandi in Men with Metastatic Hormone Sensitive Prostate Cancer: The ARCHES Trial

After a median follow-up of 14.4 months, the men who had Xtandi along with ADT experienced an improved radiographic progression-free survival advantage over those who had only ADT, regardless of their prior treatment.